triple-negative-breast-cancer

Documents about triple-negative-breast-cancer

• Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors#904379ClinicalTrials.gov
• A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors#980957ClinicalTrials.gov
• A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers#853211ClinicalTrials.gov
• A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.#373613ClinicalTrials.gov
• Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial#326119HAL (France)
• The TRIM37 variant rs57141087 contributes to triple-negative breast cancer outcomes in Black women#675944eScholarship
• MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable antitumor immunity in triple negative breast cancer#484931Europe PMC
• A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer#902398ClinicalTrials.gov
• A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)#880294ClinicalTrials.gov
• Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors#1007738ClinicalTrials.gov
• A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.#349949ClinicalTrials.gov
• A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)#980004ClinicalTrials.gov
• Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers#801878ClinicalTrials.gov
• Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients#1032968ClinicalTrials.gov
• Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI#846956ClinicalTrials.gov
• Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies#885090ClinicalTrials.gov
• A Study of NX-1607 in Adults With Advanced Malignancies#879199ClinicalTrials.gov
• Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies#256861ClinicalTrials.gov
• Data publication: "Imaging triplets on two wheels" - ⁶¹Cu-, ⁶⁴Cu-, and ⁶⁸Ga-labeled bicyclic peptides targeting Nectin-4 enable high-contrast PET imaging of urothelial carcinoma and triple-negative breast cancer#680550RODARE
• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies#830569ClinicalTrials.gov
• Analysis of molecular prognostic factors associated with tumor immune and stromal microenvironment in BEATRICE, an open-label phase 3 trial in early triple-negative breast cancer (eTNBC)#482285Figshare
• GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma#870624ClinicalTrials.gov
• A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)#802132ClinicalTrials.gov
• A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549#905067ClinicalTrials.gov
• An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors#828514ClinicalTrials.gov